CoChat

A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases

Open access
Jian, Mi, Ren, Li, He, Guodong, Lin, Qi, Tang, Wentao, Chen, Yijiao, Chen, Jingwen, Liu, Tianyu, Ji, Meiling, Wei, Ye, Chang, Wenju, Xu, Jianmin · 2020 · Journal of Translational Medicine
Cited by 78

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Backgrounds: Cancer-related mortality in patients with colorectal cancer (CRC) is predominantly caused by development of colorectal liver metastases (CLMs). How to screen the sensitive chemotherapy and targeted therapy is the key element to improve the prognosis of CLMs patients. The study aims to develop patient-derived organoids-based xenografted liver metastases (PDOX-LM) model of CRC, to recapitulate the clinical drug response. Methods: We transplanted human CRC primary tumor derived organoids in murine spleen to obtain xenografted liver metastases in murine liver. Immunohistochemistry (IHC) staining, whole-exome and RNA sequencing, and drug response testing were utilized to identify the homogeneity in biological and genetic characteristics, and drug response between the PDOX-LM models and donor liver metastases. Results: We successfully established PDOX-LM models from patients with CLMs. IHC staining showed that positive expression of CEA, Ki67, VEGF, FGFR2 in donor liver metastases were also well preserved in matched xenografted liver metastases. Whole-exon sequencing and transcriptome analysis showed that both xenografted and donor liver metastases were highly concordant in somatic variants (≥ 0.90 frequency of concordance) and co-expression of driver genes (Pearson’s correlation coefficient reach up to 0.99, P = 0.001). Furthermore, drug response testing showed that the PDOX-LM models can closely recapitulated the clinical response to mFOLFOX6 regiments. Conclusions: This PDOX-LM model provides a more convenient and informative platform for preclinical testing of individual tumors by retaining the histologic and genetic features of donor liver metastases. This technology holds great promise to predict treatment sensitivity for patients with CLMs undergoing chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12967-020-02407-8

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 78

Metadata

Authors
Jian, M., Ren, L., He, G., Lin, Q., Tang, W., Chen, Y., Chen, J., Liu, T., Ji, M., Wei, Y., Chang, W., & Xu, J.
Venue
Journal of Translational Medicine
Published
2020-06-12
Volume
18
Issue
1
Pages
234-234
ISSN
1479-5876 (ISSN-L)
OpenAlex
W3035631279
Cited by
78
References
9
FWCI
5.05
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases. https://app.cochat.ai/papers/10.1186/s12967-020-02407-8
The paper
Jian, M., Ren, L., He, G., Lin, Q., Tang, W., Chen, Y., Chen, J., Liu, T., Ji, M., Wei, Y., Chang, W., & Xu, J. (2020). A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases. Journal of Translational Medicine. https://doi.org/10.1186/s12967-020-02407-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.